Is Lantheus Holdings (LNTH) Navigating a Pivotal Transition in Radiopharmaceuticals

Related Articles

Is DHT Holdings Navigating a "Perfect Storm" in the VLCC Market

8 months ago

What is Blackstone's Latest Strategic Move in Energy Transition

7 months ago

What is Chart Industries and its Role in the Energy Transition

6 months ago

What Does CorVel's Leadership Transition Signify

4 months ago

Category

You may also like

Stock News•4 weeks ago

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

Lantheus received CMS transitional pass-through status for PYLARIFY TruVu, its PSMA PET imaging agent, alongside a permanent HCPCS code effective October 1, 2026, supporting patient access and reimbur...

LNTH

Share

News•1 months ago

Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation. Companies like JNJ and AZN, with diversified portfolios...

Share

Stock News•2 months ago

Can BWX Technologies' Nuclear Medicine Expansion Boost Growth?

BWX Technologies is expanding its commercial nuclear portfolio into nuclear medicine, isotope production, and radiopharmaceuticals, a move that could broaden its revenue base beyond defense. The expan...

BWXT

Share